Ascentage Pharma Group International (NASDAQ:AAPG) Stock Price Down 6.6% – Time to Sell?

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) shares traded down 6.6% on Wednesday. The company traded as low as $14.85 and last traded at $15.03. Approximately 4,078 shares traded hands during mid-day trading, a decline of 40% from the average daily volume of 6,815 shares. The stock had previously closed at $16.09.

Analyst Ratings Changes

A number of research analysts recently commented on AAPG shares. BTIG Research reaffirmed a “buy” rating and set a $48.00 price objective on shares of Ascentage Pharma Group International in a research report on Friday, August 21st. JPMorgan Chase & Co. lowered their target price on Ascentage Pharma Group International from $46.00 to $33.00 and set an “overweight” rating on the stock in a research note on Thursday. Two analysts have rated the stock with a Strong Buy rating and nine have issued a Buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $44.75.

Ascentage Pharma Group International Stock Performance

The company has a debt-to-equity ratio of 1.09, a current ratio of 1.22 and a quick ratio of 1.18. The business has a 50 day moving average price of $16.76 and a 200 day moving average price of $19.37.

Ascentage Pharma Group International (NASDAQ:AAPG) last announced its quarterly earnings data on Wednesday, August 19th. The company reported ($0.65) earnings per share (EPS) for the quarter. The firm had revenue of $22.24 million for the quarter. Analysts anticipate that Ascentage Pharma Group International – Unsponsored ADR will post -2.42 EPS for the current year.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a clinical-stage biopharmaceutical company focused on discovering and developing therapies that target mechanisms involved in programmed cell death. The company’s research is primarily directed toward cancer and other serious diseases in which regulating apoptosis may offer therapeutic benefits.

Its pipeline includes small-molecule drug candidates designed to inhibit proteins that help cancer cells survive. Key programs have included lisaftoclax (APG-2575), a BCL-2 inhibitor being investigated for hematologic malignancies, and APG-115, an MDM2-p53 inhibitor under evaluation in oncology indications.